Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: cetuximab
Drug: bevacizumab
Drug: FOLFIRI regimen
Drug: irinotecan
Drug: PRO95780

First Posted Date: 2007-07-06

Last Posted Date: 2017-05-19

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 20

Registration Number: NCT00497497

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: dexamethasone
Drug: floxuridine
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2007-06-27

Last Posted Date: 2024-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00492999

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

and more 1 locations

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Irinotecan
Drug: Capecitabine

First Posted Date: 2007-06-07

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT00483834

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Vinorelbine Tartrate
Drug: Gemcitabine
Drug: Bevacizumab
Drug: CPT-11
Drug: Paclitaxel

First Posted Date: 2007-05-22

Last Posted Date: 2013-07-17

Lead Sponsor: Duke University

Target Recruit Count: 16

Registration Number: NCT00476827

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Palm Beach Cancer Center Institute, West Palm Beach, Florida, United States
🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States

and more 1 locations

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Phase 1

Terminated

Conditions: Advanced Solid Malignancies
Advanced Solid Tumors
Cancer

Interventions: Drug: AZD7762
Drug: Irinotecan

First Posted Date: 2007-05-15

Last Posted Date: 2011-02-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT00473616

Locations: 🇺🇸
Research site, Nashville, Tennessee, United States
🇺🇸
Research Site, New York, New York, United States

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: irinotecan hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2012-07-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00469898

Locations: 🇺🇸
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
🇺🇸
Owensboro Medical Health System, Owensboro, Kentucky, United States
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, Canada

and more 5 locations

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Bevacizumab

First Posted Date: 2007-05-04

Last Posted Date: 2010-08-19

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 330

Registration Number: NCT00469443

Locations: 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

and more 5 locations